908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue
Business Wire•10/11/2026•07:00 ET
0
Key Highlights
- ➤Q3 revenue $19.0 million, up 35% year-over-year
- ➤2026 revenue guidance raised to $68.5 million-$70.0 million
- ➤308 devices placed, setting a new quarterly company record
- ➤Recurring revenue reached $5.1 million, or 27% of quarterly revenue
- ➤Cash, equivalents and marketable securities totaled $99.1 million, with no debt
Expert Statements
Kevin J. Knopp, CEO and Co-founder of 908 Devices
“We had a strong third quarter, driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record.”
Kevin J. Knopp, CEO and Co-founder of 908 Devices
“Our proven platforms are winning orders across the globe as customers accelerate efforts to modernize their detection capabilities and stay ahead of an evolving threat landscape.”
Kevin J. Knopp, CEO and Co-founder of 908 Devices
“NIRLab is also gaining traction, both in unit volumes and pipeline, as we build a growing base of connected, recurring revenue.”
Kevin J. Knopp, CEO and Co-founder of 908 Devices
“With continued operational discipline and healthy customer funding supporting demand, we are well positioned as we head toward the end of the year.”
908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue
908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended September 30, 2026.
Get started
Create a free account to read the full story.